PAIRED Survey of Patient-Reported Experiences With DOVATO

  • TRIAL DESIGN

    PAIRED Surveyed Patients Who Switched to DOVATO After a Previous ART1

    Patient Population
    • People living with HIV ≥18 years diagnosed with HIV-1 in the US who were receiving DOVATO for at least 3 months at the time of recruitment1
    • Previously received another ART for their HIV and classified as stable-switch (defined as individuals who had HIV-1 RNA <50 copies/mL at the time of switch)1
      • Satisfaction of prior regimen was assessed while taking DOVATO and may be subject to historical bias2
      • Sampled people living with HIV who were on DOVATO therapy for ≥3 months and could, therefore, be more likely to be predisposed to positive experiences and greater satisfaction with DOVATO2
    Recruitment Methodology1,3
    Selected Study Objectives & Methods
    • To better understand treatment experiences of people living with HIV who initiated DOVATO through a cross-sectional US survey and qualitative interviews1
      • Patients responded to questions about treatment satisfaction with DOVATO compared to their previous ART regimen, adherence, the importance of fewer medicines, and the drivers that led to switching to DOVATO1
      • The quantitative phase of PAIRED included validated instruments to assess treatment satisfaction (HIVTSQs), adherence (ADAQ), and quality of life (PoZQoL)1
      • In addition, a qualitative phase was conducted with a range of interview topics in a select subset of patients1,3

  • BASELINE CHARACTERISTICS

    Baseline Characteristics1

    Characteristics Variable
    Age ≥50 years 50%
    Female sex at birth 31%
    Race, n (%) non-White 48%
    Length of time person has been diagnosed with HIV-1, median years (IQR) 13.5 (7.0–23.0)
    On DOVATO >12 months 62%
    Prior treatment regimen  
    On their previous treatment >12 months 73%
    Patients who switched from BIKTARVY 28%
    Patients who switched from TRIUMEQ 28%

    Additional Characteristics1

    Characteristics Variable
    Age, median years (IQR) 50.0 (37.0–58.0)
    ≥50 years 238 (50.2%)
    Gender identity, n (%)  
    Cisgender woman 140 (29.5%)
    Cisgender man 312 (65.8%)
    Transgender woman 4 (0.8%)
    Transgender man 1 (0.2%)
    Nonbinary/genderqueer 5 (1.1%)
    A gender identity not listed here 12 (2.5%)
    Race, n (%)  
    Black or African American 155 (32.7%)
    White/Caucasian 248 (52.3%)
    Multiracial 13 (2.7%)
    Another race not mentioned 58 (12.2%)
    Length of time person diagnosed with HIV-1, median years (IQR) 13.5 (7.0–23.0)

  • RESULTS

    HCP- and Patient-Led Treatment Discussions1

    Now Is the Time to Ask About Your Patients’ Treatment Experience

    These results are descriptive in nature and should not be used to infer clinical significance.

    *Other responses included: “I requested this myself” (24%); “Don’t know/I cannot remember” (2%).

    †Patients were asked to respond using a scale of 1 to 5, where 5 is extremely important and 1 is not at all important.

    Results Showed Very High Patient Satisfaction Scores1‡

    Possible Scores Could Range From 0 to 60

    Using the HIVTSQs,§ out of a maximum score of 60, the median total HIVTSQs score was 57.0 (IQR: 52.0-60.0).1 The HIVTSQs was designed specifically to measure satisfaction with medication for people living with HIV.4

    These results are descriptive in nature and should not be used to infer clinical significance.

    ‡Based on the median score from the validated HIVTSQs.

    §The HIVTSQ used in PAIRED was the 10-item HIVTSQs.

    PAIRED Survey Showed >2 Times as Many Patients Reported Being Very Satisfied With DOVATO Compared With Their Previous ART Regimen1

    Level of Satisfaction

    These results are descriptive in nature and should not be used to infer clinical significance.

    ||Patients were asked: “How satisfied are you with your current treatment?” 324/474 responded with a 6 on a scale from 0 to 6 (6 being very satisfied, 0 being very dissatisfied).

    Patients were asked: “Overall, how satisfied were you with this previous prescribed treatment for HIV (the one you were taking directly before switching to DOVATO)?” 149/474 responded with a 6 on a scale from 0 to 6 (6 being very satisfied, 0 being very dissatisfied).

ADAQ=Adelphi Adherence Questionnaire; ART=antiretroviral therapy; HCP=healthcare provider; HIVTSQs=HIV Treatment Satisfaction Questionnaires status version; IQR=interquartile range; PozQoL=positive quality of life.

References:

  1. Slim J, Brogan AP, Harper G, et al. PAIRED – patient reported experiences and perceived benefit of treatment with dolutegravir/lamivudine (DTG/3TC): a diverse sample of people with HIV-1 (PWH) reporting high treatment satisfaction, good adherence, and high quality of life. Presented at: IDWeek™ 2024; October 16-19, 2024; Los Angeles, CA. Poster P-537.
  2. Slim J, Brogan AP, Harper G, et al. PAIRED – patient reported experiences and perceived benefit of treatment with dolutegravir/lamivudine (DTG/3TC) - qualitative interviews: diverse group of people with HIV-1 (PWH) reflect on life and health. Presented at: 25th International AIDS Conference; July 22-26, 2024; Munich, Germany. Poster THPEB094.
  3. Slim J, Brogan AP, Harper G, et al. PAIRED – patient reported experiences and perceived benefit of treatment with dolutegravir/lamivudine (DTG/3TC): a sub-analysis of people with HIV (PWH) switching from bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in the United States (US). Presented at: HIV Drug Therapy Glasgow; November 10-13, 2024; Glasgow, Scotland. Poster.
  4. Woodcock A, Bradley C. Validation of the revised 10-item HIV Treatment Satisfaction Questionnaire status version and new change version. Value Health. 2006;9(5):320-333. doi:10.1111/j.1524-4733.2006.00121.x

PMUS-DLLWCNT250020 March 2026